High-Throughput Testing for Unknown Mutagens and Cytotoxica via Duplex Planar Ames-Cytotoxicity Bioassay Including Metabolic S9 Activation.

Summary

This paper introduces a duplex planar Ames–cytotoxicity assay with integrated human/rat S9 that detects unknown mutagens and cytotoxicants in complex consumer matrices at high throughput. It dramatically reduces time, labor, and costs, and reveals exposure scenarios in cosmetics that may exceed half-maximal mutagenicity doses by ≥4 orders of magnitude.

Key Findings

• Developed a duplex planar Ames–cytotoxicity bioassay with substance zone fixation and dual end-point tetrazolium readout.
• Integrated human and rat liver S9 systems to assess metabolic de/activation effects on mutagenicity.
• Reduced time-to-result 5-fold, manual work 330-fold, and consumable costs 651-fold versus state-of-the-art assays.
• Unmasked previously unknown mutagens/cytotoxica in complex matrices including teas, cosmetics, creams, and perfumes.
• Estimated daily exposure to 11.5 g of skin care products exceeded the ED50 for mutagenicity by at least 10,000-fold.

Clinical Implications

While preclinical, this assay can prioritize safety concerns for dermatologic products, guide reformulation to remove mutagenic components, and support regulatory submissions with mechanistically relevant, metabolically competent data.

Limitations

• Clinical and in vivo correlations of detected mutagenicity were not reported in the abstract.
• Full validation against regulatory standard Ames formats and inter-lab reproducibility details were not provided in the abstract.

Future Directions

Standardize assay parameters and inter-laboratory ring trials, expand to additional metabolic systems, and integrate exposure assessment models to translate findings into risk thresholds for cosmetics.